News & Trends - Pharmaceuticals
Novo Nordisk summit calls for a collective vision on obesity

Pharma News: The Novo Nordisk Summit gathered local delegates from hearts4heart, Australian Patient Advocacy Alliance (APAA), and the Australian Diabetes Society (ADS), in Copenhagen. The two-day event for A Collective Vision for Obesity brought together diverse stakeholders to reinforce collaboration in tackling the mounting challenges associated with obesity.
Wegovy (semaglutide 2.4 mg) is the first GLP-1 receptor agonist available for chronic weight management. As Professor John Dixon, Vice President of the National Association of Clinical Obesity Services (NACOS), recently put it, “What we’ve had is a situation where people living with obesity have been shamed, blamed and told that they’re not really worthy of treatment.”
Tanya Hall, CEO of hearts4heart, emphasised the Summit’s potential to drive long-term impact, stating, “The Summit for A Collective Vision for Obesity was an opportunity to address obesity to benefit future generations, family well-being and workforce participation. Obesity is a critical risk factor of heart disease and serious complications such as heart attacks.”
She added, “It was a pleasure to connect with other patient organisations across the globe and be inspired by their passion and dedication to improving health outcomes for those living with obesity.”
Throughout the Summit, stakeholders delved into health equity for those affected by obesity, the cost-effectiveness of obesity interventions, and the need for policy change to recognise obesity as a chronic disease. Discussions also highlighted the latest scientific advancements in obesity treatment and management.
A keynote speech by Robyn Littlewood, CEO of Health and Wellbeing Queensland (HWQ), showcased Queensland’s community-led initiatives aimed at promoting healthy lifestyles and obesity prevention. Engaging with Novo Nordisk’s global CEO, Lars Fruergaard Jørgensen, Littlewood highlighted HWQ’s pioneering work on the global stage.
The event also explored comparative research from Germany, France, Japan, Canada, and Brazil, focusing on three key societal areas affected by obesity: family well-being, future generations, and workforce participation. These focus areas, the Summit emphasised, represent critical points for structural interventions to shift the conversation from individual responsibility to collective accountability in promoting health and respect.
In a recent interview with Health Industry Hub, Cem Ozenc, Corporate Vice President & General Manager, Oceania at Novo Nordisk, confronted the stark reality of obesity as a chronic disease and shed light on the severe gaps in Australia’s approach to this escalating health crisis.
“A [National Obesity Strategy] strategy means nothing if we don’t resource it and if we don’t put the right political leadership behind it,” Ozenc stated.
Meanwhile, Novo Nordisk faces legal challenges in the US related to Wegovy’s adverse side effects. With these issues at the forefront, the company remains focused on building the right strategy to ensure that the right patients that would benefit most from Wegovy have access to it.
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - MedTech & Diagnostics

Labor’s one-off funding a band aid for public hospitals while private sector left in limbo
The Federal Government has committed a one-off funding boost of $1.7 billion to public hospitals under a one-year extension to […]
MoreNews & Trends - Pharmaceuticals

AI-powered test to reshape use of hormone therapy in prostate cancer
Australian researchers are pioneering the use of artificial intelligence (AI) to enhance decision-making in prostate cancer treatment, specifically focusing on […]
MoreNews & Trends - MedTech & Diagnostics

Vantive debuts as standalone business amid complex landscape of chronic kidney disease
Vantive, formerly Baxter’s Kidney Care business, has officially launched as a standalone company. The move follows Baxter’s completion of the […]
MoreNews & Trends - MedTech & Diagnostics

Optalert unveils test for sleep apnoea as Philips expands partnership in pharmacy program
An Australian medical technology company has introduced a test designed to identify obstructive sleep apnoea (OSA), broadening access to sleep […]
More